The NanoBioCel group of the UPV/EHU has edited and published a book that analyses emerging approaches related to these technologies.
The increasing availability and decreasing costs of 3D printing and bioprinting technologies are expanding opportunities to meet medical and pharmaceutical needs. The book edited by researchers from the UPV/EHU’s NanoBioCel group analyses emerging approaches related to these revolutionary technologies in areas such as drug development, medical devices, bioreactors, regenerative medicine and tissue engineering.
Jose Luis Pedraz Muñoz, Laura Saenz del Burgo Martínez, Gustavo Puras Ochoa and Jon Zarate Sesma, research staff of the Nanobiocel group at the Faculty of Pharmacy of the University of the Basque Country and members of the CIBER BBN and the ICTS Nanbiosis, have edited the book ‘3D Printing and Bioprinting for Pharmaceutical and Medical Applications’, which analyses the new approaches related to these revolutionary technologies in areas such as the development of drugs, medical devices, bioreactors, regenerative medicine and tissue engineering.
The volume provides an overview of applications, market and regulatory analysis, and reviews market research on 3D printing and bioprinting technologies. It also reviews the 3D printing of new pharmaceutical forms for personalised therapies and medical devices, as well as the benefits of 3D printing for educational purposes.
In the words of the editors, «the book covers 3D bioprinting technology, including the design of decellularised polymers and matrices for bioink development, 3D modelling for drug screening, and 3D bioprinting for musculoskeletal, cardiovascular, central nervous system, ocular and skin applications. It provides a risk-benefit analysis of each application, and highlights bioreactors, regulatory issues, frontiers and challenges.» This book is an ideal reference for students, researchers and professionals in materials science, bioengineering, medical, pharmaceutical and healthcare industries.